Printer Friendly
The Free Library
6,673,365 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Steven A. Kriegsman.


Steven A. Kriegsman, president and chief executive of CytRx Corp., received the Lou Gehrig Memorial Award The Lou Gehrig Memorial Award was created by the Phi Delta Theta Fraternity in honor of the former Major League Baseball player Lou Gehrig, who was a member of the fraternity at Columbia University.  from the Muscular Dystrophy Association The Muscular Dystrophy Association (MDA) is an organization founded in 1950 which combats muscular dystrophy and diseases of the nervous system and muscular system in general by funding research, providing medical and community services, and educating health professionals . The award was presented in honor of CytRx's dedication to finding a cure for Lou Gehrig's disease Lou Geh·rig's disease
n.
See amyotrophic lateral sclerosis.
.
COPYRIGHT 2006 CBJ, L.P.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Kudos
Publication:Los Angeles Business Journal
Date:Nov 13, 2006
Words:38
Previous Article:Port of Los Angeles.(Transportation)
Next Article:Willis Ware.(Kudos)
Topics:



Related Articles
Investor Is Making Mark In Small-Cap Biotech Stocks.(Brief Article)
The Kriegsman Group.(Sorrells Pickard Gourmet Peanut Butter Co.)(Brief Article)
Transitions.(appointments and resignations)(Brief Article)
For a change, merger adds firm to L.A. corporate list. (Wall Street West).(Kriegsman Group acquires CytRx Corp.)(Brief Article)
BRIEFCASE $5 MILLION NET LOSS POSTED BY CYTRX.(Business)
CytRx Corp.(Pharmaceutical)(appointments)(Brief Article)
West Pharmaceutical Services.(MANAGEMENT)
Biotech success could lead to CytRx payoff, but there's risk.(Company Profile)
CytRx hits home run with deal on Lou Gehrig disease drug.(HEALTH CARE & BIOTECH)(ALS Charitable Remainder Trust)
CytRx creates subsidiary for gene-silencing technology: RXi will focus on RNAi interference for treatment of diseases.(DEVELOPMENT)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles